Immix Biopharma · deck
Immix Biopharma | Investor Presentation Deck | 64 slides
64 pages · 5 arc beats · 3 loops
Immix Biopharma | Investor Presentation Deck | 64 slides
Immix Biopharma · 2024-01 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
15101520253035404550556064
Deck intelligence map
5 coverage by narrative range · generated from this deck JSON
Narrative range 63 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Situation & Context 5 slides 100% 5/5 slides 100% 5/5 slides · 21 hits — 0/5 slides
60% 3/5 slides 20% 1/5 slides 100% 5/5 slides — 0/5 slides
Problem & Complication 2 slides 100% 2/2 slides 100% 2/2 slides · 11 hits — 0/2 slides
100% 2/2 slides 50% 1/2 slides 100% 2/2 slides 100% 2/2 slides Solution & Approach 10 slides 100% 10/10 slides 100% 10/10 slides · 55 hits — 0/10 slides
10% 1/10 slides 50% 5/10 slides 100% 10/10 slides — 0/10 slides
Evidence & Proof 18 slides 100% 18/18 slides 100% 18/18 slides · 81 hits — 0/18 slides
16.7% 3/18 slides · 4 hits 66.7% 12/18 slides 100% 18/18 slides 38.9% 7/18 slides Impact & Next Steps 28 slides 100% 28/28 slides 100% 28/28 slides · 140 hits — 0/28 slides
25% 7/28 slides 35.7% 10/28 slides 100% 28/28 slides — 0/28 slides
Slide inventory
64 every slide · same image gating as the playbook
01
Includes company logo, tagline, mission statement, date, and ticker symbol.front_matter
Open slide detailBeat · Situation & Context
03
The slide uses a numbered list format to present key company milestones and clinical data points.summarize
Open slide detailBeat · Situation & Context
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.other
Open slide detailBeat · Situation & Context
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).present_solution
07
The slide uses a hub-and-spoke diagram to centralize the problem of neurotoxicity.frame_problem
08
Includes flow cytometry plots and bar charts showing efficacy.present_solution
09
The slide highlights the structural modification of the binding domain in NXC-201 compared to the reference Abecma.compare_peers
Open slide detailBeat · Solution & Approach
10
The slide uses a schematic diagram to map specific protein domains to their functional benefits.present_solution
Open slide detailBeat · Solution & Approach
11
Includes citations from Nature Signal Transduction and Targeted Therapy and Nature Medicine.present_solution
Open slide detailBeat · Solution & Approach
12
The slide uses a combination of bar charts for preclinical data and a summary table for clinical outcomes to demonstrate the superiority of NXC-201.compare_peers
Open slide detailBeat · Solution & Approach
13
The slide highlights the structural advantage of the HSL configuration using a (GGGGS)5 linker.present_solution
Open slide detailBeat · Solution & Approach
14
The diagram highlights four key clinical outcomes: no Parkinson's-like symptoms, short hospital stays, broad hospital access, and no deaths in clinical trials.summarize
Open slide detailBeat · Solution & Approach
15
The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.compare_peers
Open slide detailBeat · Solution & Approach
16
The slide uses a biological illustration to highlight structural differences in binding domains and intracellular signaling components.compare_peers
Open slide detailBeat · Solution & Approach
17
Includes comparative data points for CAR-T characteristics.present_solution
Open slide detailBeat · Solution & Approach
18
The chart illustrates the pharmacokinetics of the NXC-201 (HBI0101) therapy, highlighting a 30-day clearance window.analyze_data
Open slide detailBeat · Solution & Approach
19
The slide uses a process flow diagram to connect cellular pathology to clinical manifestations.frame_problem
Open slide detailBeat · Evidence & Proof
20
The diagram shows a summation of ~29,712 (prevalence) and ~3,040 (derived from incidence) to reach ~32,752 eligible patients.size_opportunity
Open slide detailBeat · Evidence & Proof
21
The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.size_opportunity
Open slide detailBeat · Evidence & Proof
22
The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.compare_peers
Open slide detailBeat · Evidence & Proof
23
The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.compare_peers
Open slide detailBeat · Evidence & Proof
24
The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.compare_peers
Open slide detailBeat · Evidence & Proof
25
The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.compare_peers
Open slide detailBeat · Evidence & Proof
26
Includes a footnote citing FDA approval precedents for similar single-arm studies.plan_implementation
27
The slide uses a before-and-after visual comparison to illustrate market expansion.size_opportunity
28
Includes detailed source citations in the footer.compare_peers
29
The slide uses a two-column layout to separate milestones for two distinct drug programs.plan_implementation
30
The slide uses a standard pharmaceutical pipeline table format to communicate clinical progress and regulatory milestones.present_solution
31
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.size_opportunity
32
The slide uses a wave-like visual to represent market segments and their associated dollar values.size_opportunity
33
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.compare_peers
Open slide detailBeat · Evidence & Proof
34
The table uses a red dashed box to highlight key clinical efficacy and safety metrics (ORR, CR, ICANS, CRS).compare_peers
Open slide detailBeat · Evidence & Proof
35
The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.compare_peers
Open slide detailBeat · Evidence & Proof
36
The slide uses a two-column layout to contrast clinical outcomes for two different indications, followed by a row of competitor product logos and financial metrcompare_peers
Open slide detailBeat · Evidence & Proof
37
The chart illustrates deepening responses in patients treated with NXC-201 over time.analyze_data
Open slide detailBeat · Impact & Next Steps
38
The slide uses a combination of biological pathway diagrams, pharmacokinetic data, and efficacy metrics to demonstrate the therapeutic advantage of IMX-110.present_solution
Open slide detailBeat · Impact & Next Steps
39
The slide uses a numbered list format to present clinical milestones and market opportunities.summarize
Open slide detailBeat · Impact & Next Steps
41
Uses icon-based visualization to represent market expansion.size_opportunity
Open slide detailBeat · Impact & Next Steps
42
The slide uses a process flow diagram to illustrate dose escalation steps.present_solution
Open slide detailBeat · Impact & Next Steps
43
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS) acanalyze_data
Open slide detailBeat · Impact & Next Steps
44
The table highlights specific adverse events (CRS and ICANS) within a red dashed box.compare_peers
Open slide detailBeat · Impact & Next Steps
45
Highlights NXC-201's lower fludarabine dose (25 mg vs 30 mg) and Carvykti's longer infusion window (5-7 days vs 5 days).compare_peers
Open slide detailBeat · Impact & Next Steps
48
The slide uses a bar chart to contrast the combined annual sales of two groups of oncology drugs.size_opportunity
Open slide detailBeat · Impact & Next Steps
49
The slide uses three distinct bar charts to compare IMX-110 performance against standard of care or competitor drugs in preclinical mouse models.analyze_data
Open slide detailBeat · Impact & Next Steps
50
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.illustrate_case
Open slide detailBeat · Impact & Next Steps
51
Includes survival curves (Kaplan-Meier style), tumor imaging, and median survival metrics.compare_peers
Open slide detailBeat · Impact & Next Steps
52
Includes clinical trial data visualization with PFS (Progression Free Survival) and PD/PR thresholds.analyze_data
Open slide detailBeat · Impact & Next Steps
53
The slide uses a scatter plot to map clinical trials and a table to detail standard-of-care metrics by line of therapy.compare_peers
Open slide detailBeat · Impact & Next Steps
54
The slide compares clinical outcomes for patients across different lines of treatment, emphasizing high disease control and zero drug-related toxicity.analyze_data
Open slide detailBeat · Impact & Next Steps
55
Includes logos for BeiGene and Novartis.plan_implementation
Open slide detailBeat · Impact & Next Steps
56
Includes comparative size diagram of IMX-111 vs IgG antibody, bar chart of GLUT1 expression by tissue, box plot of GLUT1 expression by stage, and Kaplan-Meier spresent_solution
Open slide detailBeat · Impact & Next Steps
57
Includes two sets of charts: tumor volume line charts and survival curves.illustrate_case
Open slide detailBeat · Impact & Next Steps
58
Includes multiple citations and diagrams of molecular mechanism and clinical trial results.present_solution
Open slide detailBeat · Impact & Next Steps
59
The slide compares efficacy data for Humira, Stelara, and Entyvio against their respective placebo groups.compare_peers
Open slide detailBeat · Impact & Next Steps
61
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.present_solution
Open slide detailBeat · Impact & Next Steps
62
The process is presented as a non-linear, snake-like flow (1-5 left-to-right, 6-10 right-to-left).present_framework
Open slide detailBeat · Impact & Next Steps
63
The slide uses a 3-pillar framework to categorize the platform's foundation, leading to specific product applications.present_solution
Open slide detailBeat · Impact & Next Steps
64
Includes company logo, tagline, mission statement, date, and ticker symbol.front_matter
Open slide detailBeat · Impact & Next Steps